TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04366934

Intervention type: OTHER
Intervention: Nasal swab
Description: Nasal swab

Intervention type: OTHER
Intervention: Nasal swab
Description: Nasal swab

Intervention type: OTHER
Intervention: Taste and olfactory function evaluation
Description: Taste and olfactory function evaluation

Intervention type: OTHER
Intervention: Taste and olfactory function evaluation
Description: Taste and olfactory function evaluation
Study: NCT00537420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Placebo
Description: Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsules will be taken once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYY3-36
Description: Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYY3-36
Description: Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYY3-36
Description: Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: Sibutramine will be taken once daily with or without food
Study: NCT00999427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
Study: NCT06231056

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic iNatal®
Description: iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
Study: NCT00421395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-hLL2
Description: weekly dosing for either 2 or 3 weeks
Study: NCT03103139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpapillary Stent
Description: ERCP with placement of short stent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent across bile leak
Description: ERCP with long stent
Study: NCT02325570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Description: Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling and Root Planing (SRP)
Description: Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Study: NCT02441907

Intervention type: DRUG
Group type: OTHER
Intervention: aflibercept
Study: NCT03978741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yōni.Fit Test Device
Description: The Yōni.Fit Test Device is a silicone pessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yōni.Fit Comparator Device
Description: The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
Study: NCT00832598

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FACBC PET and [18F]FLT PET imaging
Description: \[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
Study: NCT02531360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-815 (MNI-815)
Description: All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
Study: NCT03129698

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib 250mg daily
Study: NCT04412369

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive cardiac imaging
Description: Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
Study: NCT03640520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACETS: Pediatric Resuscitation
Description: Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
Study: NCT00056316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Education
Description: Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
Study: NCT02787005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT01804933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: profound neuromuscular blockade
Description: Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
Study: NCT02787005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT01231971

Intervention type: DRUG
Intervention: Florbetapir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetapir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetapir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetapir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetapir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Flortaucipir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Flortaucipir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study: NCT00833612

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Counterpulsation with IAB
Description: IABC pre-reperfusion PCI
Study: NCT01231971

Intervention type: DRUG
Intervention: Flortaucipir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Flortaucipir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Flortaucipir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study: NCT01804933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: profound neuromuscular blockade
Description: Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
Study: NCT01731340

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: 750mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dietary Calcium
Description: 450 mg
Study: NCT04116372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Online Platform
Description: The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Online Platform
Description: The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity
Study: NCT01379482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Description: 3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)
Study: NCT03387189

Intervention type: OTHER
Intervention: Quality Improvement Project
Description: Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
Study: NCT00084396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study: NCT01731340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dietary Calcium
Description: 1200 mg
Study: NCT00084396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03660618

Intervention type: DEVICE
Group type: OTHER
Intervention: laser speckle flowgraphy
Description: blood flow state of the skin as real time two dimensional image
Study: NCT00137800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774 (Tarceva)
Description: Once daily without interruption as long as there is no disease progression or serious side effects experienced.
Study: NCT03177512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LYNX Mobile App
Description: Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
Study: NCT02497365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin and Cefazolin
Description: Fortified Tobramycin and Cefazolin eye drops
Study: NCT04599803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verily Sleep Apnea (VSA) Program/App
Description: The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
Study: NCT04094493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vit D
Description: preoperative intra muscular vit D injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vit D
Description: preoperative intra muscular vit D injection
Study: NCT03626012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT05052463

Intervention type: OTHER
Intervention: electrolyte imbalance analysis
Description: ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance

Intervention type: OTHER
Intervention: electrolyte imbalance analysis
Description: ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance

Intervention type: OTHER
Intervention: electrolyte imbalance analysis
Description: ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance

Intervention type: OTHER
Intervention: electrolyte imbalance analysis
Description: ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance

Intervention type: OTHER
Intervention: electrolyte imbalance analysis
Description: ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
Study: NCT02173483

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quadriceps graft

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quadriceps graft
Study: NCT03587428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-A toothpaste
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-B toothpaste
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.

Intervention type: OTHER
Group type: OTHER
Intervention: Mineral water
Description: Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Study: NCT00733733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG Fresenius
Description: One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
Study: NCT01375816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI 1-Bevacizumab
Study: NCT03305913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet
Study: NCT02933489

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo AB-MR

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo AB-MR

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02098928

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hand-acupuncture
Description: Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand-acupuncture
Description: Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrico-acupuncture
Description: Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrico-acupuncture
Description: Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
Study: NCT01375816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome-encapsulated irinotecan hydrochloride PEP02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT05527782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified TPF
Description: modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment (QoL)
Description: Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
Study: NCT00729911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation ablation
Description: Radio-frequency catheter ablation of atrial fibrillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Taken orally on a daily basis.